Section one: Contracting authority
one.1) Name and addresses
SOMERSET NHS FOUNDATION TRUST
Musgrove Park Hospital
Taunton
TA15DA
Contact
Hollie Caddy
servicesteam.procurement@SomersetFT.nhs.uk
Country
United Kingdom
Region code
UKK23 - Somerset
NHS Organisation Data Service
RH5
Internet address(es)
Main address
https://www.somersetft.nhs.uk/
one.4) Type of the contracting authority
Body governed by public law
one.5) Main activity
Health
Section two: Object
two.1) Scope of the procurement
two.1.1) Title
WID-Easy Somerset Pilot
Reference number
PATH018
two.1.2) Main CPV code
- 85111300 - Gynaecological hospital services
two.1.3) Type of contract
Services
two.1.4) Short description
Provision of a full end to end testing service, including sampling kit supply, sample transport, and result reporting.
two.1.6) Information about lots
This contract is divided into lots: No
two.1.7) Total value of the procurement (excluding VAT)
Value excluding VAT: £435,000
two.2) Description
two.2.2) Additional CPV code(s)
- 85111800 - Pathology services
two.2.3) Place of performance
NUTS codes
- UKK23 - Somerset
Main site or place of performance
Somerset NHS foundation Trust Sites
two.2.4) Description of the procurement
Provision of a full end to end testing service, including sampling kit supply, sample transport, and result reporting.
The WID®-easy test is a new, minimally invasive test available in the UK that uses a simple vaginal swab to help detect or rule out the risk of endometrial (womb) cancer in women experiencing abnormal bleeding. It is a far less intrusive procedure, providing faster links to the appropriate clinical pathway.
A service evaluation project would aim to test the initial adoption of the WID®-easy test at the Somerset NHS Foundation Trust. The WID®-easy test will be the frontline triage methodology for all women referred to the Trust 45 years or older with AUB and determine the next step in the clinical workflow.
This notice is an intention to award a contract under the most suitable provider process.
The approximate lifetime value of the contract is £435,000.00.
This is a new service with a new provider.
The dates between which the services are intended to be provided are between March 2026 and March 2027.
two.2.5) Award criteria
Cost criterion - Name: most suitable provider process / Weighting: 100
two.2.11) Information about options
Options: Yes
Description of options
1 x 12 month extension
Section four. Procedure
four.1) Description
four.1.1) Type of procedure
Award of a contract without prior publication of a call for competition in the cases listed below
- The procurement falls outside the scope of application of the regulations
Explanation:
This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award. The standstill period begins on the day after the publication of this notice. Representations by providers must be made to decision makers by 25 February 2026. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR'.
four.1.8) Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: No
Section five. Award of contract
Title
WID-Easy Somerset Pilot
A contract/lot is awarded: Yes
five.2) Award of contract
five.2.1) Date of conclusion of the contract
13 February 2026
five.2.2) Information about tenders
Number of tenders received: 1
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor
Advanced Global Health Limited
30 Gt. Guildford Street
London
SE1 0HS
Country
United Kingdom
NUTS code
- UKI - London
Companies House
07181386
The contractor is an SME
No
five.2.4) Information on value of contract/lot (excluding VAT)
Initial estimated total value of the contract/lot: £435,000
Total value of the contract/lot: £435,000
Section six. Complementary information
six.3) Additional information
This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award. The standstill period begins on the day after the publication of this notice. Representations by providers must be made to the relevant authority by 25 February 2026. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR.'
Representations should be sent: servicesteam.procurement@SomersetFT.nhs.uk
Award decision-makers; Cancer Programme Manager.
No conflicts or potential conflicts of interest of individuals making the decision were identified.
The key criteria were weighted as follows:
30 % Quality and Innovation
20 % Value
20 % Integration, Collaboration and Service Sustainability
20 % Improving access, reducing health inequalities and facilitating choice
10 % Social value
Quality and Innovation were weighted highest, with particular emphasis on the potential for earlier diagnosis and improved patient experience being key. Considerable emphasis was also placed on Integration with existing gynaecology and cancer pathways, alongside overall Value, recognising their importance in delivering a coherent, efficient, and sustainable service model.
The rationale for choosing the provider with reference to the key criteria:
They are uniquely capable of safely delivering the required WID‑easy/WID‑qEC triage testing at scale, and best meet the PSR key criteria of quality, value, integration and social value. Their clinically validated pathway for peri‑ and post‑menopausal women with abnormal uterine bleeding is already in operation, with UK evidence showing substantial reductions in unnecessary hysteroscopies while maintaining cancer detection, thereby improving patient experience and safety and supporting earlier diagnosis ambitions. The provider holds the necessary accredited laboratory infrastructure, high‑throughput capacity and data‑governance arrangements to deliver rapid turnaround times, integrate results into existing gynaecology and cancer pathways, and collaborate with local NHS partners on training, audit and service development, ensuring a proportionate, efficient and sustainable solution that represents best value for the public. They are currently the only provider of this service in the UK.
six.4) Procedures for review
six.4.1) Review body
Somerset NHS Foundation Trust
Musgrove Park Hospital
Taunton
TA1 5DA
Country
United Kingdom
six.4.2) Body responsible for mediation procedures
NHS England
Wellington House, 133-135 Waterloo Rd
London
SE1 8UG
Country
United Kingdom